The clinical translation of HOTTIP-based therapies faces several barriers, including limited understanding of its precise molecular mechanisms across diverse cancer types, the potential for off-target effects due to its widespread role in gene regulation, and challenges in delivering RNA-targeting therapies effectively in vivo. Here, HOTTIP is linked to cancer.